PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine

Document Type

Conference Proceeding

Publication Date

12-2020

Publication Title

Value in Health

Abstract

Objectives: Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) pathway, has demonstrated efficacy in adults with episodic or chronic migraine in clinical trials and has been approved for migraine prevention in adults. However, real-world data on the effectiveness of fremanezumab are limited. This retrospective, observational cohort study assessed patient-reported headache frequency and healthcare resource utilization (HCRU) before and after fremanezumab treatment initiation. Methods: Data were extracted from September 2018 through June 2020 from the EMRClaims+®, an integrated health services database containing over 20 million medical records from national commercial insurance claims, Medicare claims, and regional electronic medical records. Patients included in the cohort analysis were aged ≥18 years and were administered fremanezumab, with enrollment or treatment history for ≥6 months prior to initiating fremanezumab (index date), and enrollment or treatment encounter for ≥1 month after the index date. Headache frequency was assessed at baseline and ≥1 month after fremanezumab initiation. Wilcoxon-signed rank tests were used to compare means of headache frequencies before and after fremanezumab initiation. Results: A total of 54 patients were eligible for analysis of headache frequency. Overall headache frequency decreased by 63% after fremanezumab initiation: mean (standard deviation [SD]) headache frequency was 22.24 (9.29) days per month pre-index versus 8.24 (7.42) days per month post-index (P <0.0001). Mean ER visits per month decreased from 0.72 to 0.54 (P = 0.003), and mean outpatient visits per month decreased from 1.04 to 0.81 (P = 0.0004). While mean hospitalizations per month also decreased, the result did not reach statistical significance (P = 0.095). Conclusions: Significant reductions in headache frequency and HCRU were observed after fremanezumab initiation overall and across episodic and chronic migraine groups in a real-world setting.

Volume

23

Issue

Suppl 2

First Page

S640

This document is currently not available here.

Share

COinS